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ORIGINAL

ARTICLE

The Personalised Acne Care
PathwaydRecommendations to guide
longitudinal management from the
Personalising Acne: Consensus
of Experts
Jerry Tan, MD,a,b Andrew Alexis, MD, MPH,c Hilary Baldwin, MD,d,e Stefan Beissert, MD,f
Vincenzo Bettoli, MD,g James Del Rosso, DO,h,i Brigitte Dreno, MD, PhD,j Linda Stein Gold, MD,k
Julie Harper, MD,l Charles Lynde, MD,m,n Diane Thiboutot, MD,o Jonathan Weiss, MD,p and
Alison M. Layton, MB ChBq,r
Windsor and Markham, Ontario, Canada; New York and Brooklyn, New York; New Brunswick, New
Jersey; Las Vegas, Nevada; Detroit, Michigan; Birmingham, Alabama; Hershey, Philadelphia; Snellville,
Georgia; Dresden, Germany; Ferrara, Italy; Nantes, France; and York and Harrogate, United Kingdom
Background: Acne is a chronic disease with a varying presentation that requires long-term management.
Despite this, the clinical guidelines for acne offer limited guidance to facilitate personalized or longitudinal
management of patients.
Objectives: To generate recommendations to support comprehensive, personalized, long-term patient
management that address all presentations of acne and its current and potential future burden.
Methods: The Personalising Acne: Consensus of Experts panel consisted of 13 dermatologists who used a
modified Delphi approach to reach consensus on statements related to longitudinal acne management. The
consensus was defined as $75% voting ‘‘agree’’ or ‘‘strongly agree.’’ All voting was electronic and blinded.
Results: Key management domains, consisting of distinct considerations, points to discuss with patients,
and ‘‘pivot points’’ were identified and incorporated into the Personalised Acne Care Pathway. Long-term
treatment goals and expectations and risk of (or fears about) sequelae are highlighted as particularly
important to discuss frequently with patients.
Limitations: Recommendations are based on expert opinion, which could potentially differ from patients’
perspectives. Regional variations in health care systems may not have been captured.
Conclusions: The Personalised Acne Care Pathway provides practical recommendations to facilitate the
longitudinal management of acne, which can be used by health care professionals to optimize and
personalize care throughout the patient journey. ( JAAD Int 2021;5:101-11.)
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also mitigate this additional burden on patients.22
Acne, one of the most common skin conditions
Management strategies that optimize short-term and
treated by dermatologists and
long-term outcomes have
other health care profesalso been identified by
CAPSULE SUMMARY
sionals (HCPs), generally afconsensus between clinifects adolescents and young
cians and patients as a key
adults, but it can persist later
research priority, providing a
Despite the varying presentations and
in adulthood despite treatfurther rationale for develfrequently chronic nature of acne,
ment.1-5 Clinically, acne typioping a care pathway that
established clinical guidelines offer little
facilitates longitudinal pacally presents in various
guidance to facilitate its personalized
tient management.23
forms, with truncal acne preand longitudinal patient management
senting in more than half of
As a part of the 2020-2021
Based on consensus recommendations,
the patients with facial
consensus project, the Perthe Personalized Acne Care Pathway
involvement.6-11 Despite its
sonalising Acne: Consensus
panel has developed a Personalized Acne
of Experts (PACE) panelists
varying presentations and
Care Pathway to support comprehensive,
have developed a care
chronic nature, current guidepersonalized, and long-term
pathway based on expert reclines offer little guidance to
management of acne
ommendations to support
facilitate personalized or loncomprehensive, personalized,
gitudinal management of
longitudinal management of
patients.6,12,13
acne considering both the current and potential future
Personalized care is important in chronic skin
burden of disease.
conditions, where treatment success is highly dependent on patient adherence to ongoing treatment
regimens.14 Adherence to treatment can be influMATERIALS AND METHODS
enced by numerous factors, including the patients
Expert panel
themselves (their characteristics and beliefs), the
The expert panel consisted of 13 dermatologists
HCP-patient relationship, and treatment-related facfrom Canada (n = 2), France (n = 1), Germany (n = 1),
Italy (n = 1) the United Kingdom (n = 1), and the
tors such as effectiveness, acceptability, side-effect
United States (n = 7). Two chairpersons from the
profile, tolerability, frequency of use, duration, and
main panel oversaw the process and were involved
administration routes.15 Moreover, disease chronicity
in panel selection and Delphi design.
and the disease itself (including its anatomic location) play an important role, as can the health care
system in which the patient is receiving care (eg,
The modified Delphi process
appointment availability and treatment costs).11,15,16
The modified Delphi process used by the PACE
panel has been described previously.24,25 Between
Low adherence can be due to a perceived lack of
February 2020 and November 2020, 5 e-surveys were
response or low treatment satisfaction, highlighting
conducted to gather information and capture voting
the need for HCPs to consider and discuss patients’
responses, with a virtual group meeting held beconcerns, set realistic expectations, and dispel mistween the third and fourth e-survey. The PACE
conceptions throughout their treatment journey.17,18
panelists attended 2 virtual meetings to refine the
Ongoing care is also important in managing acne
pathway further and completed a workmat activity in
effectively to minimize disease relapse.19 It is addibetween (Fig 1). An initial literature search was
tionally needed due to the prolonged nature of the
conducted to inform the e-survey content and is
treatment, generally taking several months to
described in detail in the Supplementary Material
achieve optimal results.20 Patients often misperceive
(available via Mendeley at https://data.mendeley.
their acne as a short-term condition, emphasizing the
com/datasets/fy6mnvt7t7/1).
need for open and candid communication between
HCPs and patients to clarify the long-term nature of
management.21 Devising and implementing longE-survey development and administration
term care plans that consider the risk and presence of
Consensus statements were structured to assess
acne sequelae early in the treatment journey may
the level of agreement using the response range:

INTRODUCTION

d

d
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Abbreviations used:
HCP:
PACE:
PACP:

health care professional
Personalising Acne: Consensus of Experts
Personalised Acne Care Pathway

‘‘strongly disagree,’’ ‘‘disagree,’’ ‘‘agree,’’ ‘‘strongly
agree,’’ or ‘‘unable to answer.’’ The consensus was
defined as $75% voting ‘‘agree’’ or ‘‘strongly agree.’’
Some questions were posed as multiple-choice
where several responses could be selected, for
which results are presented as consensus when
chosen by $75% of panelists. Some questions were
open-ended to allow for the development of
consensus statements in a subsequent round of
voting. The programming, administration, and
response collation of the e-surveys was performed
by Ogilvy Health UK to maintain blinding.
Longitudinal management and patient types were 2
of the 4 major topics explored and will be the focus
of this manuscript. Acne sequelae and truncal acne
were also covered and have been previously
reported.24,25

RESULTS
Definition of consensus recommendations
Consensus statement voting information is provided in parentheses (eg, 12/13 voted ‘‘agree’’ or
‘‘strongly agree’’). Some panel members occasionally
voted ‘‘unable to answer’’; these votes were not
included in the denominator. Complete statements
are available in the Supplementary Material.

Elements that were considered but not voted on
are included in the ‘‘Discussion points’’ below.
Baseline demographics
When the panelists were asked about clinical
practice guidelines, 38% (n = 5) did not find them
useful for long-term management strategy, and 62%
(n = 8) did not find them useful for the management
of different patient types.
Current challenges and gaps in the
longitudinal management of acne
The PACE panel highlighted several challenges in
the longitudinal management of acne, including the
variable presence of clinical lesions, presence of
sequelae, multifactorial pathophysiology, and lack
of a definitive treatment target to utilize in a treat-totarget approach. The panelists agreed that there is a
need for educational materials for patients on the
longitudinal nature of acne management to help
them make informed decisions around choice and
modification of treatment (13/13).
Overview of the Personalised Acne Care
Pathway
Key management domains were identified across
the acne patient journey, consisting of distinct
considerations, points to discuss with patients, and
‘‘pivot points’’ (defined as a central point on which a
management decision depends). The 7 identified
management domains were mapped against the
patient journey to form the Personalised Acne Care
Pathway (PACP) (Fig 2).

Fig 1. The modified Delphi process used by Personalising Acne: Consensus of Experts panel.
PACP, Personalised Acne Care Pathway.
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Fig 2. Overview of the PACP. Based on consensus recommendations and discussion from the
Personalising Acne: Consensus of Experts panel, 7 key domains consisting of distinct
consideration points to discuss with patients and ‘‘pivot points’’ (defined as a central point
on which a management decision depends) were identified and incorporated into the PACP.
AE, Adverse event; OTC, over-the-counter; PACP, Personalised Acne Care Pathway.
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Table I. Determining patient profileddetailed
considerations and discussion points

Table II. Topics to consider for discussion at each
consultation

Consider

Discuss

d

d
d

d

d
d
d
d

Acne location
B Facial vs truncal: assess independently* (13/13)
Presence/risk of acne-induced scarring* (13/13)
Family history
B Patients with a family history of acne may be at
increased risk of sequelae or uncontrolled disease
Skin phototype
B For example, acne-induced macular hyperpigmentation in patients with darker skin phototypes
(Fitzpatrick scale IV-VI)* (13/13)
Duration of acne
Length of previously unsuccessful treatment
Socioeconomic status
Parent/child dynamic

d
d
d

d
d
d
d
d
d
d

Discuss
d

History taking
B Age and duration of acne
B Acne location
B Current acne severity vs ‘‘average day’’
B Prior and current treatments and the length of use
B Prior adverse effects or tolerability issues
B Level of discomfort/burden/quality of life issues
B Menstrual cycle irregularities
B Menstrual flares
B Signs of hyperandrogenism
B Family history of acne* (13/13) and sequelae
B Lifestyle triggers
B Allergies
B Comorbidities and concomitant medications
B Use of cosmetics, moisturizers, hair products, and
sunscreen* (12/13)
B Knowledge of acne pathogenesis
B Whey protein use
B Supplement use
B Previous endocrinological workup

*Indicates topics that were voted on via the Delphi process
(Comprehensive list of statements available as Supplementary
Material via Mendeley at https://data.mendeley.com/datasets/
fy6mnvt7t7/1).

Self-management and entry into the medical
pathway
Discussion points. Patients frequently attempt
to treat their acne with over-the-counter medications
or home remedies recommended by friends and
family, or on social media, for some time before
presenting to an HCP. Patients eventually present to a
dermatology specialist through various pathways,
including internet searches, advertising (eg, television or social media), word of mouth, or referral from
a primary care practitioner or pharmacist.

d
d

Patient-reported satisfaction with acne treatment
Administration/application technique* (12/13)
Treatment goals and expectations:
B It is of paramount importance to discuss long-term
treatment expectations with acne patients* (13/13)
B Treatment goals and expectations should be discussed with patients at the first consultation and
revisited frequently* (13/13)
Efficacy expectations (including timelines)* (12/13)
Duration of treatment* (12/13)
Adverse effects/tolerability* (12/13)
Importance of adherence* (12/13)
Daily skincare routine* (13/13)
Risk of sequelae
Changes to patient’s general medication (eg, contraception) or diet
Cost of treatment
Access to treatment

*Indicates topics that were voted on via the Delphi process
(Comprehensive list of statements available as Supplementary
Material via Mendeley at https://data.mendeley.com/datasets/
fy6mnvt7t7/1).

Determining patient profile
Detailed considerations and discussion points for
HCPs to determine patient profiles are provided in
Table I.
Discussion points. Early and comprehensive
assessment of the patient’s profile is important for
optimizing care. Many of the factors concerning
patient history could bed and often aredcompleted
before the patient enters the consultation. Several
factors such as acne location, patient demographics/
specific clinical presentations, medical and family
history, skin phototype, and prognostic risk factors
can be assessed relatively quickly in a consultation.
More time-consuming elements include building and
strengthening the HCP-patient rapport, explaining
the multifactorial and chronic nature of acne, managing treatment expectations, and ensuring that
patients are satisfied with their treatment, feel
supported, and understand that the HCP is invested
in helping their acne improve.
Topics to consider for discussion at each
consultation
Topics that HCPs should consider discussing with
patients at each consultation are provided in Table II.
Discussion points. The panel identified several
patient-related factors, including patient-reported
satisfaction, treatment goals and expectations, and
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Table III. Treatment initiation/modification phasedgaps and detailed considerations, discussion points, and
pivot points
Gaps
d

d

There is a need for high-quality evidence for when to escalate, switch, or de-escalate both acne initiation and maintenance
treatment* (12/13)
Common reasons for nonadherence to initiation and maintenance treatment include treatment intolerance (eg, local
irritation)* (13/13), perceived lack of efficacy* (11/13), and perceived difficulty of use/inconvenience* (10/13)

Consider
d
d
d
d
d
d
d
d
d

Acne type and severity
Acne location (facial and/or truncal acne)
Patient preference
Burden of disease* (13/13)
Risk or presence of sequelae
Factors that may affect adherence to treatment (including prior adherence)
Degree of seborrhoea/oiliness
Skin sensitivity
Comorbidities

Discuss
d

d

d

d

d

Goal setting
B The goals of initiation treatment are to achieve clear or almost-clear skin (depending on patient acceptability) with
no new acne lesions and to reduce the risk of sequelae* (13/13)
B Personalized treatment goals depending on the specific impact of acne in certain regions* (13/13)
B Any immediate short-term goals (eg, wedding)
Managing expectations
B It is of paramount importance to discuss long-term treatment expectations with acne patients* (13/13)
Treatment
B All options should be discussed (including over-the-counter and holistic treatments) based on patient preferences
Antibiotic resistance
B Prescribers should discuss antibiotic resistance with patients who are prescribed an antibiotic for acne* (13/13)
Potential reasons for prior nonadherence to acne medications with patients and adjust their management accordingly*
(13/13)

Pivot points

In an ideal situation, patients should be followed up within 3 months where possible during the initiation phase of
treatment
d Consider increasing the frequency of follow-up when there are safety or tolerability concerns, adherence issues, the
patient is particularly anxious or distressed if there is a high risk of sequelae, severe acne, or a lack of efficacy (with current
or previous treatments)
d Consider decreasing the frequency of follow-up when the treatment is well tolerated, the patient is stable, there is lack of
evidence of sequelae development, adherence is good, or for reasons where the patient cannot return for appointments
easily (such as going away to college)
d Consider the period over which a prescribed treatment is expected to have an effect
Review, assess, modify
d Switching treatment
B Consider when there is a lack of response* (13/13), the patient is unsatisfied or unhappy with the response* (10/13),
adverse effects or issues with tolerability occur* (12/13), or the patient desires to switch treatment* (11/13)
d Escalating treatment
B Consider when there is an inadequate response* (13/13) or the patient is unhappy or unsatisfied with the response*
(12/13)
d De-escalating treatment
B Consider when there are adverse effects/issues with tolerability* (10/13) or a patient desire to de-escalate treatment*
(10/13)
d Stopping treatment
B Consider when treatment goals that were set together with the patient have been met* (11/13), satisfactory efficacy
outcomes have been achieved* (10/13), adverse effects or issues with tolerability occur* (10/13), or the patient
desires to stop treatment* (11/13)
d

*Indicates topics that were voted on via the Delphi process (Comprehensive list of statements available as Supplementary Material via
Mendeley at https://data.mendeley.com/datasets/fy6mnvt7t7/1).
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Table IV. Maintenance treatment/modification phasedgaps and detailed considerations, discussion points,
and pivot points
Gaps
d
d
d

d

d

There is a need for guidance on the most appropriate time to initiate maintenance therapy* (12/13)
Clinical practice guidelines do not provide sufficient guidance on the choice of acne maintenance treatment* (12/13)
Clinical practice guidelines do not provide sufficient guidance on when to escalate, switch, or de-escalate acne
maintenance treatment* (13/13)
There is a need for high-quality evidence for when to escalate, switch, or de-escalate both acne initiation and maintenance
treatment* (12/13)
Common reasons for nonadherence to initiation and maintenance treatment include treatment intolerance (eg, local
irritation)* (13/13), perceived lack of efficacy* (11/13), and perceived difficulty of use/inconvenience* (10/13)

Consider
d

d
d
d
d
d

Clinical indicators to start maintenance treatment
B Goals of the initiation phase of treatment achieved
B Patient satisfaction with treatment response, treatment regimen, and appearance
Duration of treatment with antibiotics
Age/sex of patient (and associated risk of active acne returning)
Patient preference
Completion of the isotretinoin treatment course
Ongoing cost of treatment

Discuss
d

Goal setting
B The goals of the maintenance phase are to maintain clear/almost-clear skin achieved during the initiation phase, to
prevent acne from returning to a level that is unacceptable to the patient, and to reduce the risk of acne sequelae*
(13/13)

Pivot points

In an ideal situation, patients should be followed up at least twice a year during the maintenance phase of treatment
Consider increasing the frequency of follow-up when there are safety or tolerability concerns or adherence issues, when
the patient is particularly anxious or needs encouragement, if sequelae develop, or when there is a lack of efficacy or
return of active acne to a level unacceptable to the patient
d Consider decreasing the frequency of follow-up when the patient is stable, when the agreed treatment goals have been
met, or for reasons where the patient cannot return easily for appointments (such as going away to college)
Review, assess, modify
d Switching treatment
B Consider when there is a lack of response* (10/13), the patient is unsatisfied or unhappy with the response* (10/13),
there are adverse effects/issues with tolerability* (12/13), or there is poor acceptability of treatment (eg, oiliness,
odor, and bleaching/staining)* (10/13)
d Switching from maintenance back to initiation treatment
B Consider when there is a lack of response (eg, acne returning to premaintenance state)* (13/13) or the patient is
unsatisfied or unhappy with the response* (11/13)
d
d

*Indicates topics that were voted on via the Delphi process (Comprehensive list of statements available as Supplementary Material via
Mendeley at https://data.mendeley.com/datasets/fy6mnvt7t7/1).

risk of (or fears about) sequelae, as important factors
to discuss with patients at each consultation.
Goal setting should involve shared decisionmaking as goals can vary widely among individuals,
with the HCP responsible for negotiating with the
patient about what is realistically achievable.
HCPs should prioritize discussion topics based on
how the individual patient is responding to the

prescribed treatment and should enquire about any
important changes to their daily routine.
Treatment initiation/modification phase
The treatment initiation/modification phase is
defined as the regimen (which may include a number of different treatments) undertaken to achieve a
primary goal before maintenance therapy. Gaps and
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detailed considerations, discussion points, and pivot
points for the treatment initiation/modification
phase are included in Table III.
Discussion points. It was highlighted that during this phase there is also a need to allow for an
adjustment period to a medication. As such, the
period over which the prescribed medication would
be expected to have an effect is an additional factor
to consider when determining how frequently to
follow-up with patients. In some cases, treatment deescalation can also be considered in patients when
an adequate response has been achieved.

DECEMBER 2021

Table V. Sequelae managementddetailed
considerations, discussion points, and pivot points
Consider
d
d
d

Discuss
d

d

Maintenance treatment/modification phase
The maintenance phase is defined as the regimen
(which may include a number of different treatments) undertaken to maintain the response
achieved by initiation treatment (13/13). Gaps and
detailed considerations, discussion points, and pivot
points for the maintenance treatment/modification
phase are included in Table IV.
Discussion points. Tele-visits are an acceptable
platform for follow-up visits if patients are progressing well on maintenance treatment.
d

Treatment discontinuation
Treatment discontinuation can be considered
when the treatment goals that have been mutually
developed and agreed by the clinician and patient
have been met.
Sequelae management
Detailed considerations, discussion points, and
pivot points for sequelae management are included
in Table V.
Discussion points. Sequelae management has
been previously reported in detail.25
Additional considerations for patients with
specific clinical presentations
Patient types that require additional considerations for their acne management are provided in
Table VI.
Discussion points. All patients should be
managed using an individualized approach; however, the panel identified a number of specific clinical
presentations that may require additional
considerations.

DISCUSSION
This PACP represents a consolidated effort to
provide expert recommendations for the longitudinal management of acne. It incorporates patientcentered goals, reviewing, assessing, and modifying
treatment, a transition from initiation to maintenance

Risk factors for sequelae
Impact on quality of life
Skin phototype

Acne sequelae should be discussed with patients at the
first consultation and revisited frequently
Managing expectations:
B Discuss their concerns around the effect of their
disease* (11/13)
B Discuss their concerns around treatment* (10/13)
B Discuss their expectations from treatment* (11/13)
B Highlight that improvement may only be observed
in the long term* (10/13)
B Be realistic with them about outcomes* (11/13)
B Emphasize the need for control of active acne to
reduce the risk of developing sequelae* (13/13)
B Emphasize the role of modifiable risk factors (eg,
lesion excoriation, adherence to medication) in
reducing the risk of developing sequelae* (13/13)
B Discuss management options for sequelae* (10/13)
Discuss correction procedures with patients

Pivot points
d

Consider whether the patient needs time for existing
lesions to heal

*Indicates topics that were voted on via the Delphi process
(Comprehensive list of statements available as Supplementary
Material via Mendeley at https://data.mendeley.com/datasets/
fy6mnvt7t7/1).

therapy, and guidance on how to manage patients in
cases of relapse or remission. Alternative terminology has been previously used to describe the
treatment initiation/modification phase in the PACP
(eg, induction treatment); however, the recommendations for this treatment phase remain the same.6
Current clinical guidelines for acne recommend
treatment primarily based on disease-related factors,
such as the type of acne and severity of disease, at
fixed time points during the treatment journey, and
almost exclusively focus on facial acne, with little
guidance regarding the treatment of truncal
acne.6,12,13 The PACP complements clinical guidelines by addressing all presentations of acne and
providing a framework to manage patients in a
dynamic and holistic way, taking into consideration
treatment- and patient-related factors as well as the
current and future burden of disease. The PACE
panel has previously provided recommendations to
improve the management of truncal acne and acne
sequelae.24,25 These recommendations highlighted

JAAD INT

Tan et al 109

VOLUME 5

Table VI. Additional factors to consider for patients with specific clinical presentations
Patients with specific clinical presentations

Children aged \10 years* (12/13)
Patients with darker skin phototypes
(Fitzpatrick scale IV-VI)* (13/13)

Patients with hormonal conditions*
(13/13)
Heavy exercisers/athletes* (11/13)
Patients at risk of psychiatric issues*
(10/13)

Women who are pregnant or
breastfeeding (11/13)
Transgender patients* (12/13)
Patients with medication-induced
acne* (10/13)
Adult male patients
Adult female patients

Consider

Lack of established skin care routine and potential hormonal conditions* (11/13)
d Acne-induced macular hyperpigmentation* (13/13)
d Additional hyperpigmentation caused by irritation from topical medication* (11/
13)
d Potential inappropriate use of bleaching creams* (10/13)
d Cultural cosmetic practices that may influence acne (eg, the use of oils in hair)*
(11/13)
d Difficulty in counteracting the effects of exogenous androgens* (12/13)
d The need for interdisciplinary management with an endocrinologist* (11/13)
d Requirements for laboratory examinations* (12/13)
d Potential use of anabolic steroids or supplements* (12/13)
d The potential to be engaging in harsh cleaning routines or excoriation/
manipulation of lesions* (12/13)
d Drug-induced acne* (10/13)
d The need for interdisciplinary management with a psychiatrist or other allied
health care professionals* (12/13)
Recommendations for considerations not explored further
d

Recommendations for considerations not explored further
Patients with medication-induced acne (including those receiving cancer
treatment, eg, epidermal growth factor receptor inhibitors)* (10/13)
d Steroid or supplement-induced acne* (11/13)
d Use of hormonal treatments (eg, contraception)* (13/13)
d Potential polycystic ovary syndrome* (12/13)
d Use of make-up and other cosmetic skincare products* (11/13)
d Pregnancy and lactation* (12/13)
Specific populations of acne patients may benefit from an interdisciplinary approach to management (11/12)
d

*Indicates topics that were voted on via the Delphi process (Comprehensive list of statements available as Supplementary Material via
Mendeley at https://data.mendeley.com/datasets/fy6mnvt7t7/1).

the importance of addressing truncal acne and acne
sequelae as early as possible in the patient journey to
mitigate the additional physical and psychosocial
burden imposed on patients.26,27 In addition, given
that understanding patient expectations and mutually determined goals is inextricably linked to a
positive HCP-patient relationship, the PACP is designed to cultivate a shared commitment to care
personalized to each patient.15,17,28 As such, it is
important to emphasize that the PACP is not intended
to act as a substitute for clinical guidelines and advise
on specific treatment recommendations but instead
is intended to provide guidance in optimizing the
process of care in clinical practice.
Patient satisfaction with treatment is one of the
most important aspects to consider in ongoing management to improve adherence to treatment regimens; however, this is multifactorial and includes
whether patients are satisfied with the improvement
in their acne with the treatment regimen and whether
they are satisfied with their appearance.15,17,18
Currently, the majority of treatment algorithms in
national and regional clinical management guidelines do not incorporate patient-oriented treatment

goals or patient satisfaction as an outcome.6,12,13,29-39
Thus the PACE panel has recommended addressing
patient satisfaction in consultations to improve
adherence and ultimately improve patient outcomes.
A limitation is that the recommendations outlined
in the PACP are based on the experiences of the
expert panel and reflect HCP perspectives on the
important topics to discuss with patients, which
could potentially differ from patients’ perspectives.28
In addition, although the PACP integrates recommendations from an international group of experts, it
only represents the health care systems in which the
PACE panel has the experience and may not account
for nuances in other regions.40,41 Similar strengths
and limitations of the Delphi method apply, as
previously reported.24,25
The PACP represents a simple, clear, and comprehensive overview of the acne patient journey, which
emphasizes the multistep nature of acne management. Future applications for the PACP could include
the development of iterations of the pathway for
different audiences, for example, a version for
patients, primary care practitioners, or nurses. This
could be particularly helpful for patients (especially
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adolescents) to emphasize that their journey with
acne could be an ongoing and dynamic process.
Patient cases to demonstrate the use of the pathway
could also be a valuable tool and have been used
previously in other dermatologic conditions, such as
rosacea.42 Practical applications of the PACP include
potential use by HCPs as an ‘‘acne care road map’’
while treating patients to accompany the patient
through their acne journey and to determine individual pivot points in partnership with the patient.
Feedback on the use of the PACP in clinical practice
will be required to inform future updates and the
development of practical tools to facilitate its use.
Digital forms of the road map could also be
developed to allow real-time support and feedback
for HCPs during discussions with patients.

CONCLUSION
The PACE panel has developed the PACP to
provide practical and actionable recommendations
to facilitate personalized, longitudinal management
of patients with acne. These recommendations can
inform local guideline development and patient
consultations, thus helping to optimize and personalize care throughout the patient journey.
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